This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
41
Universitätsherzzentrum Freiburg - Bad Krozingen
Bad Krozingen, Baden-Wurttemberg, Germany
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Medizinische Einrichtungen der Universität Bonn
Bonn, North Rhine-Westphalia, Germany
SocraTec R&D GmbH
Erfurt, Thuringia, Germany
Blood pressure
Regular measurements of blood pressure after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.
Time frame: Up to 8 weeks
Heart rate
Regular measurements heart rate after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.
Time frame: Up to 8 weeks
Number of participants with adverse events
Time frame: Up to 9 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Charité - Campus Virchow-Klinikum (CVK)
Berlin, Germany
Universitätsklinikum Hamburg Eppendorf (UKE)
Hamburg, Germany